AI English summary of an SEC filing — figures as filed
Abbott Laboratories ABTThe company said net sales excluding the impact of foreign exchange rose 12.2% in Q2 2026, citing the acquisition of Exact Sciences Corporation and high single-digit growth in Medical Devices and Established Pharmaceutical Products. Nutritional Products sales declined.
Key points
AI summaryThe company said net sales excluding the impact of foreign exchange rose 12.2% in Q2 2026, citing the acquisition of Exact Sciences Corporation and high single-digit growth in Medical Devices and Established Pharmaceutical Products. Nutritional Products sales declined.
Abbott acquired Exact Sciences for approximately $20.6 billion on March 23, 2026, the company said. It paid $105 per share in cash and funded the deal mainly with $20.0 billion of long-term debt issued in March 2026. It said it had repaid nearly all of the approximately $2.8 billion of Exact Sciences debt it assumed as of June 30.
The company said its gross profit margin percentage in Q2 2026 was 52.5%, down from 52.7% a year earlier, and cited higher intangible amortization expense related to the Exact Sciences acquisition and higher costs as factors. SG&A expenses in Q2 rose $934 million to $4.0 billion, an increase of 30.3%.
The company said cash and cash equivalents fell from $8.5 billion on December 31, 2025 to $5.1 billion on June 30, 2026. Net cash from operating activities for the first six months of 2026 was $3.8 billion, and the company repurchased about 11.6 million shares for $1.0 billion over the same period.
Key figures
Quarter ended June 30, 2026
- Revenue
- $12.6B
- Operating income
- $1.7B
- Net income
- $928M
- EPS
- $0.53
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q2 Net Sales Up 12.2% Excluding FX
The company said net sales excluding the impact of foreign exchange rose 12.2% in Q2 2026, citing the acquisition of Exact Sciences Corporation and high single-digit growth in Medical Devices and Established Pharmaceutical Products. Nutritional Products sales declined.
Source · Based on the MD&A text of the filing
Exact Sciences Acquired for About $20.6 billion
Abbott acquired Exact Sciences for approximately $20.6 billion on March 23, 2026, the company said. It paid $105 per share in cash and funded the deal mainly with $20.0 billion of long-term debt issued in March 2026. It said it had repaid nearly all of the approximately $2.8 billion of Exact Sciences debt it assumed as of June 30.
Source · Based on the MD&A text of the filing
Gross Margin 52.5%, SG&A Expenses Up 30.3%
The company said its gross profit margin percentage in Q2 2026 was 52.5%, down from 52.7% a year earlier, and cited higher intangible amortization expense related to the Exact Sciences acquisition and higher costs as factors. SG&A expenses in Q2 rose $934 million to $4.0 billion, an increase of 30.3%.
Source · Based on the MD&A text of the filing
Cash $5.1 billion, Operating Cash Flow $3.8 billion
The company said cash and cash equivalents fell from $8.5 billion on December 31, 2025 to $5.1 billion on June 30, 2026. Net cash from operating activities for the first six months of 2026 was $3.8 billion, and the company repurchased about 11.6 million shares for $1.0 billion over the same period.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…